Cypher与Taxus支架治疗冠心病的冠状动脉造影随访结果Angiographic follow-up study of the effect of the Cypher and Taxus stents in coronary antery disease
刘宏斌,盖鲁粤,金琴花,杨庭树,陈练,王禹,任艺虹,孙志军,郭军
摘要(Abstract)：
目的观察Cypher及Taxus药物洗脱支架治疗冠心病的疗效。方法应用冠状动脉造影随访162例接受Cypher及Taxus药物洗脱支架置入术的冠心病患者,其中Cypher组93例,Taxus组69例。结果Cypher组和Taxus组再狭窄率分别为10.8%和11.6%,靶病变再血管化率分别为5.4%和5.8%,两组比较差异均无统计学意义。支架内晚期管径丢失及支架节段晚期管径丢失在Cypher组低于Taxus组,两组间差异有统计学意义。结论药物洗脱支架可有效降低介入治疗术后再狭窄的发生率,但Cypher组支架内晚期管径丢失低于Taxus组。
关键词(KeyWords)： 支架;冠状动脉疾病;血管成形术,经腔,经皮冠状动脉
基金项目(Foundation):
作者(Author): 刘宏斌,盖鲁粤,金琴花,杨庭树,陈练,王禹,任艺虹,孙志军,郭军
参考文献(References)：
- 1Serruys PW.ARTSⅠ-the rapamycinelutingstent;ARTSⅡ-the rosy prophecy.Eur Heart J,2002,23:757-759.
- 2Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versusstandard stents in patients with stenosis in a native coronary artery.NEngl J Med,2003,349:1315-1323.
- 3Grube E,Silber S,Hauptmann KE,et al.TAXUSI:six-andtwelve-monthresults froma randomized,double-blind trial on a slowrelease paclitaxel-elutingstent for de novo coronarylesions.Circulation,2003,107:38-42.
- 4Bauters C,Lablanche JM,Renaud N,et al.Morphological changes after percutaneous transluminal coronary angioplasty of unstable plaques:insightsfromserial angioscopicfollow-up.Eur Heart J,1996,17:1554-1559.
- 5Ruygrok PN,Muller DW,Serruys PW.Rapamycin in cardiovascular medicine.Intern Med J,2003,33:103-109.
- 6Giannakakou P,Robey R,Fojo T,et al.Low concentrations of paclitaxel induce cell type-dependent p53,p21and G1/G2arrest instead of mitotic arrest:molecular determinants of paclitaxel-induced cytotoxicity.Oncogene,2001,20:3806-3813.
- 7Morice MC,Serruys PW,Sousa JE,et al.for the RAVEL Study Group.Arandomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med,2002,346:1773-1780.
- 8Sousa JE,Costa MA,Sousa AG,et al.Two-year angiographic and intravascular ultrasoundfollow-up after implantation of sirolimus-eluting stents in human coronary arteries.Circulation,2003,107:381-383.
- 9Gregg W,Stephen G,David AC,et al.One-year clinical results with the slow-release,polymer-based,paclitaxel-eluting TAXUS stent the TAXUS-Ⅳtrial.Circulation,2004,109:1942-1947.